OVT-101
Ovarian Cancer & Other Solid Tumors
Pre-clinicalActive
Key Facts
About OverT Bio
OverT Bio is a private, pre-clinical stage biotech founded in 2021, headquartered in San Diego, CA, with a secondary office in New York, NY. The company is developing a differentiated platform that integrates AI-driven functional genomics, multimodal receptor design, and gamma delta T cells to create off-the-shelf cell therapies targeting solid tumors. With a lead program, OVT-101, anticipated to enter first-in-human trials in H1 2027, OverT aims to overcome key challenges in solid tumor treatment such as immunosuppression, poor T cell persistence, and manufacturing scalability. The company is backed by venture capital and strategic collaborators.
View full company profile